For the quarter ending 2025-09-30, MAZE has $422,058K in assets. $42,622K in debts. $316,773K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 316,773 | 264,541 | ||
| Marketable securities | 67,162 | - | ||
| Prepaid expenses and other current assets | 7,367 | 6,609 | ||
| Total current assets | 391,302 | 271,150 | ||
| Property and equipment, net | 5,538 | 6,006 | ||
| Restricted cash | 1,089 | 1,089 | ||
| Operating lease right-of-use asset | 20,920 | 21,707 | ||
| Other assets | 3,209 | 3,567 | ||
| Total assets | 422,058 | 303,519 | ||
| Accounts payable | 2,918 | 3,666 | ||
| Operating lease liabilities, current | 4,764 | 4,718 | ||
| Accrued expenses and other current liabilities | 14,430 | 11,516 | ||
| Total current liabilities | 22,112 | 19,900 | ||
| Operating lease liabilities, net of current portion | 19,419 | 20,291 | ||
| Other liabilities, non-current | 1,091 | 1,090 | ||
| Total liabilities | 42,622 | 41,281 | ||
| Common stock, 0.001 par value 500,000,000 and 410,000,000 shares authorized as of september 30, 2025 and december 31, 2024, respectively 48,076,885 and 2,446,864 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively 10,372 shares subject to repurchase as of september 30, 2025 and december 31, 2024 | 48 | 44 | ||
| Additional paid-in-capital | 834,298 | 687,086 | ||
| Accumulated other comprehensive income | 69 | - | ||
| Accumulated deficit | -454,979 | -424,892 | ||
| Total stockholders' equity (deficit) | 379,436 | 262,238 | ||
| Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) | 422,058 | 303,519 | ||
Maze Therapeutics, Inc. (MAZE)
Maze Therapeutics, Inc. (MAZE)